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Abstract
Background: Few effective drugs are available for soil-transmitted helminthiases and drug resistance is of concern. In the
present work, we tested the efficacy of the veterinary drug monepantel, a potential drug development candidate compared
to standard drugs in vitro and in parasite-rodent models of relevance to human soil-transmitted helminthiases.
Methodology: A motility assay was used to assess the efficacy of monepantel, albendazole, levamisole, and pyrantel
pamoate in vitro on third-stage larvae (L3) and adult worms of Ancylostoma ceylanicum, Necator americanus and Trichuris
muris. Ancylostoma ceylanicum-o rN. americanus-infected hamsters, T. muris-o rAscaris suum-infected mice, and
Strongyloides ratti-infected rats were treated with single oral doses of monepantel or with one of the reference drugs.
Principal Findings: Monepantel showed excellent activity on A. ceylanicum adults (IC50=1.7 mg/ml), a moderate effect on
T. muris L3 (IC50=78.7 mg/ml), whereas no effect was observed on A. ceylanicum L3, T. muris adults, and both stages of
N. americanus. Of the standard drugs, levamisole showed the highest potency in vitro (IC50=1.6 and 33.1 mg/ml on A.
ceylanicum and T. muris L3, respectively). Complete elimination of worms was observed with monepantel (10 mg/kg) and
albendazole (2.5 mg/kg) in A. ceylanicum-infected hamsters. In the N. americanus hamster model single 10 mg/kg oral
doses of monepantel and albendazole resulted in worm burden reductions of 58.3% and 100%, respectively. Trichuris muris,
S. ratti and A. suum were not affected by treatment with monepantel in vivo (following doses of 600 mg/kg, 32 mg/kg
and 600 mg/kg, respectively). In contrast, worm burden reductions of 95.9% and 76.6% were observed following treatment
of T. muris- and A. suum infected mice with levamisole (200 mg/kg) and albendazole (600 mg/kg), respectively.
Conclusions/Significance: Monepantel reveals low or no activities against N. americanus, T. muris, S. ratti and A. suum
in vivo, hence does not qualify as drug development candidate for human soil-transmitted helminthiases.
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Introduction
The hookworm species Ancylostoma duodenale and Necator
americanus, the whipworm Trichuris trichiura, the threadworm
Strongyloides stercoralis, and the roundworm Ascaris lumbricoides are
soil-transmitted helminths (STH) of great public health impor-
tance. Cumulatively, these parasites affect more than one billion
people globally, particularly in developing regions of Asia, Africa,
and Latin America [1,2]. If untreated, infections with STH are
present for years and patients suffer from moderate to severe
intestinal disturbances, anemia, nutrient loss and profound
physical and mental deficiencies [3,4].
Helminth control relies primarily on the regular administration
of anthelmintics, typically carried out within the framework of
school-based deworming programs, once or twice a year [5–7].
Five drugs are currently available for the treatment of infections
with STH (albendazole, mebendazole, pyrantel pamoate, levam-
isole, and ivermectin), all of which have been registered for human
use before or during the 1980’s [8,9]. No new anthelmintic drug
for human use has reached the market since then. Moreover, none
of these drugs are efficacious using single doses on all STH species,
with particularly low efficacy observed on T. trichiura [10]. Relying
on only a handful of drugs is a precarious situation, in the light of a
possible emergence of drug resistance [10].
Since drug resistance to nematodes of veterinary importance is
widely spread and increasing in frequency, most of the
anthelmintic drug research and development efforts are motivated
by veterinary needs [11]. For example, albendazole, mebendazole,
and pyrantel pamoate were originally developed for livestock and
pets [12].
Monepantel (AAD1566) belongs to a new class of veterinary
anthelmintics, the amino-acetonitrile derivatives. It has been
proposed that monepantel interferes with nematode-specific
acetylcholine receptor subunits, leading to body wall muscle
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of action, the drug has proven efficacy against nematodes infecting
livestock which are resistant to current anthelmintic drugs [13].
Monepantel has been extensively tested on different nematode
isolates. Administered at a single oral dose of 2.5 mg/kg, it was
found to be safe, well-tolerated by ruminant hosts, and showed
high cure rates on fourth stage larvae and adult worms of 15
nematode species [13–16]. Due to its high and broad nematocidal
activity, monepantel was considered to be a candidate for a human
health directed program.
The aim of the present investigation was to study the activity of
monepantel, compared with the reference drugs, albendazole,
levamisole, and pyrantel pamoate, in five parasite-rodent models,
that correspond to important human STH and in vitro. Ancylostoma
ceylanicum and Necator americanus were both adapted using eggs from
infected dogs or humans to an unnatural host, the golden hamster,
and represent robust rodent models for hookworm infections
[17,18]. The Trichuris muris mouse model is an excellent model for
trichuriasis [19,20]. Strongyloides ratti in rats is a commonly used
murine model for strongyloidiasis [21]. Finally, murine infection
with Ascaris suum is a model which mimics the early infection of A.
lumbricoides. The survival of different larval stages and adult worms
of A. ceylanicum, N. americanus, and T. muris was evaluated in vitro,
following monepantel incubation using a motility assay. The in vitro
activity of monepantel on S. ratti has been described recently [22].
In vivo, we studied worm burden reductions and for A. ceylanicum, N.
americanus, and T. muris, worm expulsion rates were also measured.
Methods
Drugs
Monepantel was kindly provided by Novartis Animal Health,
St-Aubin, Switzerland. Albendazole and pyrantel pamoate were
purchased from Sigma-Aldrich (Buchs, Switzerland), and levam-
isole-hydrochloride from Fluka (Buchs, Switzerland).
For the in vitro studies, stock solutions of the drugs were prepared
in 100% DMSO (Fluka, Buchs, Switzerland) and stored at 4uC.
For the in vivo studies, drugs were suspended in 7% (v/v) Tween
80% and 3% (v/v) ethanol or DMSO/PEG shortly before
treatment.
Animals and Parasites
Three-week-old male Syrian Golden hamsters were purchased
from Charles River (Sulzfeld, Germany). Four-week-old female
NMRI mice and 3-week-old female C57Bl/6J mice were
purchased from Harlan (Horst, The Netherlands). Three-week-
old female Wistar rats were purchased from Harlan (Horst, The
Netherlands).
All animals were kept in macrolon cages under environmental-
ly-controlled conditions (temperature: 25uC, humidity: 70%,
light/dark cycle 12 h/12 h) and had free access to water and
rodent food (Rodent Blox from Eberle NAFAG, Gossau,
Switzerland). They were allowed to acclimatize in the animal
facility of the Swiss Tropical and Public Health Institute (Swiss
TPH) for 1 week before infection. The current study was approved
by the local veterinary agency based on Swiss cantonal and
national regulations (permission no. 2070).
Parasites and Infections
Ancylostoma ceylanicum third-stage larvae (L3) were kindly
provided by Prof. J. M. Behnke (University of Nottingham). The
A. ceylanicum life cycle [23] had been maintained at the Swiss TPH
since June 2009 [17]. To maintain the life cycle, hamsters were
treated orally 1 day before infection and then twice weekly with
3 mg/kg hydrocortisone (HydrocortoneH, MSD) or with 1 mg/l
dexamethasone (dexamethasone water-soluble, Sigma-Aldrich) in
the drinking water. They were orally infected with 150 A.
ceylanicum L3, which had been harvested less than 1 month before
infection and had been assessed microscopically for viability.
Animals assigned to in vivo studies were not treated with
hydrocortisone and were infected with 300 L3.
Infective N. americanus L3 were the gift of Prof. S. H. Xiao
(National Institute for Parasitic Diseases, Shanghai). Hamsters
were immunosuppressed with dexamethasone as described above
and were infected subcutaneously with 250 viable N. americanus L3.
Embryonated T. muris eggs were kindly obtained from Prof. J.
M. Behnke and Prof. H. Mehlhorn. The life cycle had been
maintained at the Swiss TPH since January 2010 as described
elsewhere [19]. Briefly, T. muris eggs were evaluated for
embryonation under the microscope (magnification 80–1606,
Carl Zeiss, Germany). NMRI mice were orally infected with 400
embryonated eggs. Mice were treated either subcutaneously (s.c.) 1
day before infection and then every second day between days 5
and 15 with 15 mg hydrocortisone (Hydrocortisone 21-hemisuc-
cinate sodium salt, Sigma-Aldrich) in 0.9% NaCl solution, or with
8 mg/l dexamethasone in the drinking water until the end of the
experiment.
The S. ratti life cycle had been maintained over decades at the
Swiss TPH, by serial passage through rats. Rats were infected
subcutaneously with 735 freshly harvested S. ratti L3.
Infective A. suum eggs were obtained from Prof. S. M.
Thamsborg, University of Copenhagen and Prof. G. Cringoli,
University of Naples. Briefly, C57Bl/6J mice were orally infected
with 500 embryonated eggs, according to a procedure described
elsewhere [24].
In vitro Studies
The larval or adult motility assay is currently the method of
choice to evaluate drug sensitivity of different nematode species
[25–27]. Non-motile worms were considered as dead and the
percent viability or survival in each well was calculated.
Author Summary
Soil-transmitted helminthiases affect more than one billion
people among the most vulnerable populations in
developing countries. Currently, control of these infections
primarily relies on chemotherapy. Only five drugs are
available, all of which have been in use for decades. None
of the drugs are efficacious using single doses against all
soil-transmitted helminths (STH) species and show low
efficacy observed against Trichuris trichiura. In addition, the
limited availability of current drug treatments poses a
precarious situation should drug resistance occur. There-
fore, there is great interest to develop novel drugs against
infections with STH. Monepantel, which belongs to a new
class of veterinary anthelmintics, the amino-acetonitrile
derivatives, might be a potential drug candidate in
humans. It has been extensively tested against livestock
nematodes, and was found highly efficacious and safe for
animals. Here we describe the in vitro and in vivo effect of
monepantel, on Ancylostoma ceylanicum, Necator amer-
icanus, Trichuris muris, Strongyloides ratti, and Ascaris suum,
five parasite-rodent models of relevance to human STH.
Since we observed that monepantel showed only high
activity on one of the hookworm species and lacked
activity on the other parasites tested we cannot recom-
mend the drug as a development candidate for human
soil-transmitted helminthiases.
Nematocidal Activity of Monepantel
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Activity against L3. Thirty L3 in 100 ml deionized water,
supplemented with antibiotics, were placed in each well of a 96-
well plate (Costar). The L3 had been harvested less than 1 month
before the studies and were stored in deionized water containing
25 mg/ml amphotericin B (Sigma-Aldrich) and 1% (v/v) penicillin-
streptomycin solution (10,000 U/ml penicillin and 10 mg/ml
streptomycin, Sigma-Aldrich). Drugs were serially-diluted in
HBSS (Gibco) supplemented with 25 mg/ml amphotericin B
(Sigma Aldrich) and 1% (v/v) penicillin-streptomycin solution
(10,000 U/ml penicillin and 10 mg/ml streptomycin, Sigma-
Aldrich). Diluted drug (100 ml; 100–0.01 mg/ml, final
concentration) were added to the wells and the plate was
incubated for 72 h at room-temperature in a dark and humid
box. Larval motility was evaluated under the microscope
(magnification 206) following addition of 100 ml hot water
(,90uC) and exposure to microscope light. A minimum of 2
wells served as controls, which were L3 incubated with the highest
concentration of DMSO used in the test (2% v/v).
Activity against Adults. Drug susceptibility on adults was
tested in 48-well plates (Costar). Three to 4 worms were added to
wells containing 500 ml supplemented HBSS medium, containing
10% v/v fetal calf serum (Gibco). Drug dilutions (500 ml) were
added and the plate was incubated for 72 h at 37uC and 5% CO2.
The motility of adult worms was evaluated under the microscope
(magnification 206), after adding 500 ml hot water (,90uC), using
a viability scale (2: good motility, 1: lowered motility, and 0: no
motility, death). A minimum of 3 worms served as controls which
were incubated in the presence of the highest concentration of
DMSO used in the test (2% v/v).
Ovicidal Activity. The drug effects on eggs were observed
using a modified protocol of the egg hatch test [28]. Stools of
infected hamsters were collected overnight, filtered and subjected to
flotation by mixing the stool with a 2 M NaNO3 solution and
centrifuged at 2000 rpm. The upper quarter of the solution
(containing the eggs) was kept and washed twice in deionized
water. The test was carried out in quadruplicate for each drug
concentration. Fifty eggs in 500 ml deionized water were distributed
to each well and 500 ml drug diluted in deionized water were added
(10 mg/ml, final concentration). After 24 and 48 h, 20 eggs per well
were examined under the microscope (magnification 80–1606) for
embryonation and hatching, respectively.
T. muris
Activity against L3 and Adults. L3 or adults were collected
from the intestines of infected mice and 3–4 worms were distributed
to each well of 48 or 96-well plates (Costar), containing 100 ml (L3)
or 500 ml (adults) RPMI medium supplemented with 5% (v/v)
amphotericin B (Sigma Aldrich) and 1% (v/v) penicillin-
streptomycin solution (10,000 U/ml penicillin and 10 mg/ml
streptomycin, Sigma-Aldrich). Drug dilutions (100 ml for testing
on L3 or 500 ml for adults) ranging from 200–50 mg/ml, final
concentration, were added and the plate was incubated for 72 h at
37uC and 5% CO2. The larval and adult motilities were evaluated
under the microscope (magnification 20–806) using a viability scale
(3: good motility, 2: low motility, 1: very low motility, and 0: death),
as described by Stepek and colleagues [27]. A minimum of 3 worms
served as controls, which were incubated in the highest
concentration of DMSO used in the test (2% v/v).
In vivo Studies
A. ceylanicum and N. americanus. The immuno-
suppressive treatment of hamsters was stopped at least 2 days
before treatment. Hamsters were housed individually from day 20
post-infection (p.i.) onwards. On days 21 and 22 (A. ceylanicum)o r
46 and 47 (N. americanus), a fecal sample was collected from each
hamster and processed using an in-house sedimentation method.
Briefly, stools were collected overnight, soaked in 0.9% NaCl
solution, filtered and washed with 150 ml saline through 8 gauze
layers. The filtrate was allowed to sediment for 1–2 h and the
solution adjusted to 0.1 g filtrate per ml. To calculate the number
of eggs per gram (epg), the average of 4 egg counts of 20 ml of fecal
solution was determined microscopically. On the basis of the fecal
egg burden, A. ceylanicum-infected hamsters were assigned to the
following treatment groups - monepantel 10 mg/kg or 5 mg/kg,
albendazole 5 mg/kg, 2.5 mg/kg or 1.25 mg/kg, levamisole
10 mg/kg or pyrantel pamoate 10 mg/kg- or control groups,
with 4 animals per group. Similarly, groups of 3–4 N. americanus-
infected animals received 20 or 10 mg/kg monepantel, 10 or
5 mg/kg albendazole, or served as controls.
Hamsters were treated on day 23 p.i. (A. ceylanicum) or 48 p.i. (N.
americanus) with single oral doses of the test drugs. Expelled worms
were counted from the collected stools 24 h and 48 h after
treatment. On day 7 post-treatment, the hamsters were killed by
the CO2 method and the remaining worms in the gut counted
[29–31].
T. muris. Treatment with dexamethasone was stopped at
least 2 days before treatment. Mice were housed individually from
day 40 onwards. A fecal sample was examined from each mouse
and egg negative animals were excluded from the study. Groups of
4 infected animals were assigned to treatment (monepantel
600 mg/kg, albendazole 600 mg/kg, levamisole 200 mg/kg, or
pyrantel pamoate 300 mg/kg) or control groups. Expelled worms
were counted from the collected stools 24 h and 48 h after
treatment. On day 7 post-treatment, mice were killed by the CO2
method and the remaining worms in the gut counted [30].
S. ratti. Five days p.i, 1 group of 4 rats was treated orally with
32 mg/kg monepantel. Four rats were left untreated and served as
controls. Seven days post-treatment, the rats were dissected. The
intestine was removed, opened and incubated for 3 h at 37uCi n
PBS, as described before [32]. The liquid and the intestines were
screened under a binocular, and the larvae counted (magnification
10–406).
A. suum. One hour p.i, 2 groups of 4 mice were treated with
single oral doses of 600 mg/kg monepantel or 600 mg/kg
albendazole. A third group of 4 mice was left untreated and
served as control. On day 7 post-treatment, the mice were killed by
the CO2 method. The lungs and livers were removed, cut with fine
scissors, and incubated in 0.9% NaCl for 24 h at 37uC to allow
larvae to migrate out of the organs into the saline [24]. Larvae in
solution were counted using a microscope (magnification 206).
Statistical Analyses
The average of motility scores for one drug was calculated for
each concentration and normalized into percentage, relative to
control. IC50 values were expressed based on the median effect
principle using CompuSyn (version 1.0). The r value represents the
linear correlation coefficient of the median-effect plot, indicating
the goodness of fit, hence the accuracy of the IC50 [33]. Variance
analysis in the ovicidal activity studies was performed with the
Fisher’s exact test, using StatsDirect (version 2.4.5; StatsDirect
Ltd; Cheshire, UK). The worm burden reductions were
determined by comparing the mean number of adult worms in
the intestine of a treated group with the mean numbers of worms
in the control group. Means and standard deviations were
calculated using MicrosoftH Excel 2003. The worm expulsion
rates were calculated by dividing the number of expelled worms of
a treatment group by the group’s total worm burden. The
Nematocidal Activity of Monepantel
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assess the statistical significance of the worm burden reduction,
using StatsDirect.
Results
In vitro Findings
The effects of monepantel and reference drugs on L3 and adult
worms of A. ceylanicum and T. muris after 72 h of exposure in vitro
are presented in Table 1.
A. ceylanicum. The sensitivity of A. ceylanicum L3 to
monepantel was low at the highest concentration tested (100 mg/
ml), with over 70% of the larvae still showing activity after 72 h
following stimulation with hot water and exposure to light
(IC50.100 mg/ml). Pyrantel pamoate affected the larvae only
moderately (IC50=90.9 mg/ml, r=0.84), whereas an IC50 of
32.4 mg/ml was calculated for albendazole (r=0.87). Levamisole
showed superior efficacy: at a concentration of 10 mg/ml a survival
rate of 26.7% was determined. An IC50 value of 1.6 mg/ml
(r=0.95) was calculated for levamisole (Table 1).
Ancylostoma ceylanicum adult worms were highly sensitive to
monepantel at concentrations of 1 mg/ml and above
(IC50=1.7 mg/ml, r=0.93). Lower activities against adult A.
ceylanicum were observed for albendazole, levamisole, and pyrantel
pamoate, which showed survival rates of 60–95% at 100 mg/ml
(all IC50s.100 mg/ml) (Table 1).
As shown in Table 2, albendazole was the only compound that
inhibited both egg embryonation and hatching in vitro (90.5% and
98.5% inhibition of embryonation and hatching, respectively).
Levamisole, pyrantel pamoate, and monepantel showed no effect
on embryonation and only a moderate inhibition on hatching
(reduction of 4.7–41.5%).
N. americanus. Neither monepantel nor albendazole had an
effect on the viability of larvae or adult N. americanus (Table 1).
Levamisole was found the most efficacious drug at both stages,
with calculated IC50s of 0.5 mg/ml (r=0.97) against larvae and
13.4 mg/ml (r=0.99) against adults. Both stages were found to be
sensitive to pyrantel pamoate (IC50s=2.0 mg/ml, r=0.94 and
7.6 mg/ml, r=0.98, respectively).
T. muris. A reduction in viability of T. muris L3 was observed
following exposure to monepantel (IC50=78.7 mg/ml, r=1.0),
whereas adult worms were not affected (IC50.200 mg/ml).
Albendazole showed no activity against T. muris L3 or adults in
vitro (IC50.200 mg/ml). The highest activity on T. muris L3 and
adults in vitro was observed with levamisole (IC50s=33.1 mg/ml,
r=1.0, and 16.5 mg/ml, r=1.0, respectively) followed by pyrantel
pamoate (IC50s=95.5 mg/ml, r=0.99 and 34.1 mg/ml, r=0.99,
respectively) (Table 1).
In vivo Findings
A. ceylanicum. The worm expulsion rates and worm burden
reductions determined for monepantel, albendazole, levamisole,
and pyrantel pamoate administered to A. ceylanicum-infected
hamsters at single oral doses are shown in Table 3. Treatment
with monepantel at 10 mg/kg resulted in complete elimination of
the worms. At a dose of 5 mg/kg a worm expulsion rate of 42.7%
and a worm burden reduction of 56.8% were observed. The worm
burden reductions in monepantel-treated hamsters were
statistically significant (P=0.046). Treatment with albendazole at
5 and 2.5 mg/kg cured all A. ceylanicum-infected hamsters. At a
dose of 1.25 mg/kg the worm expulsion rate and worm burden
reduction were 70.5% and 87.8%, respectively. There was a
highly significant difference between the worm burden of
albendazole-treated hamsters (1.25–5 mg/kg) and control
hamsters (P,0.001). Moderate activities were observed for
levamisole (worm burden reduction of 60.2%, P=0.057) and
pyrantel pamoate (worm burden reduction of 87.2%, P=0.057
and worm expulsion rate of 63.4%) administered at 10 mg/kg.
N. americanus. As presented in Table 4, no dose-response
relationship could be observed following administration of
monepantel to N. americanus-infected hamsters. Both worm
expulsion rate and worm burden reduction were 58.3% after
treatment with a single dose of 10 mg/kg monepantel, whereas a
worm expulsion rate and worm burden reduction of 38.6% and
0%, respectively were obtained following treatment with 20 mg/
Table 1. 50% inhibitory concentrations of monepantel, albendazole, levamisole, and pyrantel pamoate on A. ceylanicum, N.
americanus, and T. muris.
Drugs A. ceylanicum N. americanus T. muris
IC50 in mg/ml (r) IC50 in mg/ml (r) IC50 in mg/ml (r)
L3 Adults L3 Adults L3 Adults
Monepantel .100 (0.70) 1.7 (0.93) .100 (n.d.) .100 (0.32) 78.7 (1.0) .200 (n.d.)
Albendazole 32.4 (0.87) .100 (0.77) .100 (n.d.) .100 (0.57) .200 (0.39) .200 (0.40)
Levamisole-HCl 1.6 (0.95) .100 (0.79) 0.5 (0.97) 13.4 (0.99) 33.1 (1.0) 16.5 (1.0)
Pyrantel pamoate 90.9 (0.84) .100 (0.79) 2.0 (0.94) 7.6 (0.98) 95.5 (0.99) 34.1 (0.99)
IC50s( mg/ml) were calculated for monepantel, albendazole, levamisole, and pyrantel pamoate after 72 h on L3 and adult stages of A. ceylanicum, N. americanus, and T.
muris. r=linear correlation coefficient of the median-effect plot, indicating the goodness of fit. r$0.85 indicates a satisfactory fit. n.d.: not determined, fitting not
possible.
doi:10.1371/journal.pntd.0001457.t001
Table 2. Ovicidal activity of monepantel, albendazole,
levamisole, and pyrantel pamoate on A. ceylanicum eggs.
Group
% Embryonation
at 24 h (SD)
% Hatching
at 48 h (SD)
Control 100 (3.5) 100 (9.8)
Monepantel 99.5 (9.3) 68.6 (9.2)*
Albendazole 9.5 (5.2)* 1.5 (3.0)*
Levamisole-HCl 88.6 (8.2)* 58.5 (3.5)*
Pyrantel pamoate 95.4 (7.0) 95.3 (12.5)
SD=standard deviation.
*P-value ,0.001 (Fisher’s exact test).
doi:10.1371/journal.pntd.0001457.t002
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were not statistically significant (P=0.830). In comparison,
albendazole administered at 5 mg/kg achieved a worm
expulsion rate of 69.6% and a worm burden reduction of
70.8%. A complete elimination of worms was observed at
10 mg/kg albendazole (P=0.028).
T. muris. The worm expulsion rates and worm burden
reductions determined for monepantel, albendazole, levamisole,
and pyrantel pamoate administered to T. muris-infected mice at
single oral doses are shown in Table 5. A single dose of 200 mg/kg
levamisole resulted in a worm expulsion rate of 90.5% and a worm
burden reduction of 95.9% (P=0.036). Albendazole (600 mg/kg)
achieved a worm expulsion rate of 49.4% and a worm burden
reduction of 20.2%. No effect was observed with pyrantel pamoate
(300 mg/kg) and monepantel (600 mg/kg) (worm expulsion rate
and worm burden reduction ,10%).
S. ratti. S. ratti-infected rats treated with 32 mg/kg
monepantel showed a worm burden reduction of 0% compared
to the untreated control group (P=0.77).
A. suum. Monepantel displayed negligible effect on the worm
burden in the mice’s lungs and liver, 7 days after treatment with
600 mg/kg (worm burden reduction=3.3%, P=0.886, Table 6),
compared to the control animals. Albendazole administered at the
same dose achieved a worm burden reduction of 76.6%
(P=0.171).
Discussion
To date, only five drugs are included in the WHO model list of
essential medicines to treat infections with human STH. Most of
these anthelmintics were discovered before the 1980s. Though
there is no evidence yet for emerging resistance to any of these
drugs in human helminth populations, there are worrying signs
that anthelminthic efficacy may be declining [34,35]. In addition,
the increased frequency of reported low cure rates, in particular
against T. trichiura and hookworm infections, highlight the need to
find alternative drugs [10].
A. ceylanicum, N. americanus, T. muris, S. ratti, and A. suum are five
well-established laboratory parasite-rodent models of relevance to
human STH. The aim of the present study was to determine their
sensitivities to monepantel, a broad spectrum and safe drug used
for livestock which recently entered the market for veterinary use.
It is one of the few available drug candidates eligible for rapid
transitioning into development for human STH infections [36].
Monepantel activates signaling via nematode-specific DEG-3
subtype nicotinic acetylcholine receptors (nAChRs), causing a
hypercontraction of the body wall muscles leading to paralysis and
hence, death of the worm [13]. ACR-23 protein, a member of the
DEG-3 group in Caernohabtitis elegans, and its homolog MPTL-1 in
Haemonchus contortus, another model for gastrointestinal nematodes,
are major targets of monepantel. The absence of MPTL-1,
Table 3. Dose response relationships of monepantel, albendazole, levamisole, and pyrantel pamoate on A. ceylanicum in vivo.
Group
Dose
(mg/kg)
Mean number of
worms (SD)
Mean number of
expelled worms (SD)
Worm expulsion
rate (%)
Worm burden
reduction (%) P-value
Control 1 – 29.5 (21.2) 0 0 – –
Control 2 – 24.5 (8.8) 0 0 – –
Control 3 – 29.7 (4.2) 0.3 (0.6) 1.1 – –
Control 4 – 27.0 (4.0) 0.3 (0.6) 1.2 – –
Monepantel 5
1 22.3 (10.1) 9.5 (4.4) 42.7 56.8 0.046*
10
1 16.0 (9.7) 16.0 (9.7) 100 100
Albendazole 1.25
4 11.0 (6.9) 7.8 (3.8) 70.5 87.8 ,0.001*
2.5
3 6.3 (7.1) 6.3 (7.1) 100 100
5
2 6.3 (7.1) 6.3 (7.1) 100 100
Levamisole-HCl 10
2 17.5 (7.2) 7.8 (2.5) 44.3 60.2 0.057
1
Pyrantel pamoate 10
3 10.3 (9.3) 6.5 (6.2) 63.4 87.2 0.057
1
SD=standard deviation. The numbers in superscript refer to the corresponding control group.
*Kruskal Wallis test comparing the median of the worm burdens of control and treated hamsters (all doses versus control),
1Mann-Whitney U-test comparing the median of the worm burdens of control and treated hamsters (one dose versus control).
doi:10.1371/journal.pntd.0001457.t003
Table 4. Effects of monepantel and albendazole on N. americanus in vivo.
Group
Dose
(mg/kg)
Mean number of
worms (SD)
Mean number of
expelled worms (SD)
Worm expulsion
rate (%)
Worm burden
reduction (%) P-value*
Control – 8.0 (7.5) 0 (0) 0 – –
Monepantel 20 19.0 (12.0) 7.3 (4.5) 38.6 0 0.830
10 8.0 (4.4) 4.7 (3.1) 58.3 58.3
Albendazole 10 6.7 (2.5) 6.7 (2.5) 100 100 0.028
5 7.7 (3.1) 5.3 (3.8) 69.6 70.8
SD=standard deviation.
*Kruskal Wallis test comparing the median of the worm burdens of control and treated hamsters (all doses versus control).
doi:10.1371/journal.pntd.0001457.t004
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sensitivity [22].
Ancylostoma ceylanicum adult worms were found to be highly
sensitive to monepantel in vitro, in contrast to the third-stage larvae,
but the drug lacked ovicidal activity. Hamsters harboring adult A.
ceylanicum were cleared from the worms following a 10 mg/kg
single oral dose of monepantel. N. americanus was not affected by
the drug in vitro and only moderately susceptible in vivo to 10 mg/
kg or higher doses. These findings suggest a relative stage and
species specificity, which might be explained by the absence of a
functional MPTL-1 homolog in A. ceylanicum L3 and possibly in L3
and adult N. americanus.
Trichuris muris third-stage larvae were only moderately sensitive
to monepantel after incubation for 72 h in vitro, whereas adult
stages were not affected, neither in vitro nor in vivo. Monepantel had
already been reported to lack activity against T. ovis, a minor
parasite of sheep [15,16], a finding that is in accordance with our
data.
In addition, monepantel lacked activity in S. ratti-infected rats, a
result in line with a recent investigation, which revealed that S. ratti
third-stage larvae were not affected by monepantel after 72 h of
incubation [22]. For comparison, a complete elimination of adult
worms was achieved with ivermectin (0.5 mg/kg) in S. ratti-infected
rats [32]. Strongyloides ratti has a remote homolog of DES-2 and
ACR-23/MPTL-1 only, which is not targeted by monepantel [22].
Finally, although only one high dosage was tested, our data
indicate that A. suum is not affected by treatment with monepantel
in vivo, whereas albendazole reduced the worm burden of A. suum
in mice at the same dose.
Like H. contortus, A. ceylanicum and N. americanus are members of
the nematode clade V, whereas S. ratti belongs to clade IV, A. suum,
to clade III, and T. muris to clade I [37]. One could hypothesize
that only clade V species exhibit sensitivity to monepantel,
whereas those that diverged from this lineage of the evolutionary
tree earlier (clades I to IV) might not have evolved homologous
receptors. As available for A. suum [38], further genome
sequencing of A. ceylanicum, N. americanus and Trichuris spp. remains
to be performed in order to extend current knowledge about
evolutionary and functional relationships of receptors involved in
sensitivity to monepantel.
In the present investigation, albendazole, levamisole, and
pyrantel pamoate have been extensively studied in vitro and in
vivo. The results obtained are in agreement with earlier in vivo
[29,39–41] and in vitro [41] work using A. ceylanicum and N.
americanus. In addition, to our knowledge, the in vitro and in vivo
sensitivities of these three drugs against T. muris are presented for
the first time. In line with human efficacy data [10], albendazole
showed highly potent activity against A. ceylanicum, N. americanus
and A. suum, yet much less pronounced activity against T. muris in
vivo. A similar trend was observed for pyrantel pamoate, which
achieved a moderate effect against A. ceylanicum but lacked activity
in T. muris-infected mice. These results on pyrantel pamoate are
compatible with cure rates reported in clinical trials [10]. On the
other hand, levamisole was highly efficacious in our ancylostomi-
asis and trichuriasis rodent models, while low to moderate cure
rates have been recently reported in humans [10,42].
Interestingly, contradictory results were obtained with albenda-
zole, levamisole, and pyrantel pamoate against adult A. ceylanicum
in vitro and in vivo. In addition, albendazole showed excellent
activity in the N. americanus hamster model but lacked activity in
vitro. This finding might be partially explained by the presence of
active metabolites, since for example albendazole and levamisole
are rapidly metabolized in vivo [43–45]. In addition, large
differences in sensitivity between larval and adult hookworm
stages were observed with levamisole (and albendazole for A.
ceylanicum). It is commonly accepted that the benzimidazoles tend
to be lethal to developing stages but not always to adult worms.
Developing cells are obviously more harmed by the benzimid-
azoles, as the utilization of tubulin in the mitotic cycles is affected
[46].
Table 5. Effects of monepantel, albendazole, levamisole, and pyrantel pamoate on T. muris in vivo.
Group
Dose
(mg/kg)
Mean number of
worms (SD)
Mean number of
expelled worms (SD)
Worm expulsion
rate (%)
Worm burden
reduction (%) P-value
1
Control – 90.0 (41.5) 1.0 (1.2) 0 – –
Monepantel 600 106.6 (159.1) 1.7 (0.6) 1.6 0 0.536
Albendazole 600 140.3 (116.6) 69.3 (48.1) 49.4 20.2 0.536
Levamisole-HCl 200 29.0 (60.9) 26.3 (54.6) 90.5 95.9 0.036
Pyrantel pamoate 300 282.3 (246.6) 26.7 (20.6) 9.4 0 0.095
SD=standard deviation.
1Mann-Whitney U test comparing the median of the worm burdens of control and treated mice.
doi:10.1371/journal.pntd.0001457.t005
Table 6. Effects of monepantel and albendazole on A. suum in vivo.
Group
Dose
(mg/kg)
Mean number of worms
following treatment (SD)
Worm burden
reduction (%) P-value
1
Control – 48.4 (37.33) – –
Monepantel 600 46.8 (21.33) 3.3 0.886
Albendazole 600 11.35 (13.26) 76.6 0.171
SD=standard deviation.
1Mann-Whitney U test comparing the median of the worm burdens of control and treated mice.
doi:10.1371/journal.pntd.0001457.t006
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analyzed the efficacy of monepantel in animal models correspond-
ing to human intestinal helminthiases. A recently developed target
product profile suggested that a drug development candidate for
the treatment of infections with STH should ideally target all
stages (at least adult and ova) and species of the major
geohelminths such as Ascaris, Trichuris, both hookworm species
and Enterobius [36]. Hence, based on our results, established in
nematode-rodent models, monepantel does not fulfill the required
minimal product characteristics for a new intestinal anthelmintic.
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